Stonebridge Capital Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Stonebridge Capital Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$118K	Hold	17,500	–	–	0.01%	209
2025 Q4	$139K	Hold	17,500	–	–	0.01%	210
2025 Q3	$120K	Hold	17,500	–	–	0.01%	213
2025 Q2	$68.3K	Hold	17,500	–	–	0.01%	215
2025 Q1	$66.3K	Hold	17,500	–	–	0.01%	208
2024 Q4	$95K	Hold	17,500	–	–	0.01%	213
2024 Q3	$73.3K	Sell	17,500 -2,500	-13%	-$9.23K	0.01%	221
2024 Q2	$59K	Hold	20,000	–	–	0.01%	215
2024 Q1	$55.4K	Hold	20,000	–	–	0.01%	223
2023 Q4	$56.8K	Hold	20,000	–	–	0.01%	214
2023 Q3	$51.6K	Buy	+20,000	New	+$64.2K	0.01%	357

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Stonebridge Capital Advisors's DMAC Position: Q1 2026 in Review

Stonebridge Capital Advisors held its DiaMedica Therapeutics (DMAC) position steady in Q1 2026 at 17,500 shares worth $118K. The position accounts for 0.01% of the portfolio, ranked #209.

Stonebridge Capital Advisors first reported a position in DMAC in Q3 2023 and has held it in 11 quarters since. The position peaked at $139K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Stonebridge Capital Advisors held 17,500 shares of DiaMedica Therapeutics worth $118K as of Q1 2026.
Stonebridge Capital Advisors left its DiaMedica Therapeutics share count unchanged in Q1 2026.
DiaMedica Therapeutics made up 0.01% of Stonebridge Capital Advisors's portfolio in Q1 2026, its #209 holding.
Stonebridge Capital Advisors first reported a position in DiaMedica Therapeutics in Q3 2023 and has held it in 11 quarters since.
Stonebridge Capital Advisors's DiaMedica Therapeutics position peaked at $139K in Q4 2025.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Stonebridge Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.